Table 2.
Endpoint | Subgroup | n | Events | Event rate | AUC |
Added value of penkid |
|
---|---|---|---|---|---|---|---|
Screata | penkida | P value | |||||
MAKE | All | 579 | 169 | 29% | 0.831 [0.795, 0.867] | 0.838 [0.802, 0.874] | <0.001 |
No CKD | 500 | 121 | 24% | 0.815 [0.771, 0.859] | 0.818 [0.774, 0.862] | <0.001 | |
eGFR >75 | 180 | 7 | 4% | 0.504b[0.246, 0.722] | 0.700 [0.480, 0.905] | 0.048 | |
SOFA = 0 | 212 | 13 | 6% | 0.637b[0.459, 0.811] | 0.779 [0.639, 0.919] | <0.001 | |
SOFA = 0/1 | 336 | 37 | 11% | 0.704 [0.617, 0.793] | 0.749 [0.665, 0.832] | <0.001 | |
AKI | All | 582 | 360 | 62% | 0.948 [0.929, 0.967] | 0.854 [0.823, 0.884] | <0.001 |
No CKD | 502 | 284 | 57% | 0.936 [0.912, 0.959] | 0.826 [0.791, 0.862] | <0.001 | |
eGFR >75 | 180 | 18 | 10% | 0.627 [0.453, 0.800] | 0.624b[0.484, 0.762] | 0.052 | |
SOFA = 0 | 212 | 30 | 14% | 0.621b[0.483, 0.755] | 0.736 [0.634, 0.839] | <0.001 | |
SOFA = 0/1 | 337 | 138 | 41% | 0.898 [0.858, 0.939] | 0.761 [0.709, 0.813] | <0.001 | |
WRF | All | 576 | 142 | 25% | 0.734 [0.688, 0.781] | 0.778 [0.733, 0.822] | <0.001 |
No CKD | 497 | 106 | 21% | 0.714 [0.660, 0.768] | 0.755 [0.703, 0.808] | <0.001 | |
eGFR >75 | 178 | 10 | 6% | 0.539b[0.341, 0.752] | 0.694 [0.506, 0.880] | 0.032 | |
SOFA = 0 | 209 | 16 | 8% | 0.485b[0.286, 0.618] | 0.739 [0.608, 0.873] | <0.001 | |
SOFA = 0/1 | 334 | 40 | 12% | 0.649 [0.555, 0.741] | 0.715 [0.631, 0.799] | <0.001 |
AKI, acute kidney injury; AUC, area under the curve; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; penkid, proenkephalin A 119-159; Screat, serum creatinine; SOFA, Sequential Organ Failure Assessment; WRF, worsening renal function.
AUC with 95% confidence intervals.
P > 0.05; all other univariate P < 0.05.